Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
Independent Director of Tango Therapeutics Mace Rothenberg Buys 400% More Shares
The Analyst Landscape: 5 Takes On Tango Therapeutics
B.Riley Financial Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Cuts Target Price to $8
Tango Therapeutics(TNGX.US) 10% Shareholder Sells US$8.44 Million in Common Stock
$Tango Therapeutics(TNGX.US)$ 10% Shareholder EcoR1 Capital, LLC sold 2.7 million shares of common stock on Nov 6, 7, 2024 at an average price of $3.1243 for a total value of $8.44 million.Source: